Showing 1 - 7 results of 7 for search '"злокачественная артериальная гипертензия"', query time: 0.55s Refine Results
  1. 1
    Academic Journal

    Source: Ophthalmology in Russia; Том 15, № 4 (2018); 455-462 ; Офтальмология; Том 15, № 4 (2018); 455-462 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2018-4

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/772/543; Tsai H.M. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev. 2014;28(4):187–197. DOI:10.1016/j.tmrv.2014.08.004; Brocklebank V., Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J. 2017;10(5):600–624. DOI:10.1093/ckj/sfx081; Shen Y.-M. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016;14 (Suppl. 1):19. DOI:10.1186/S 12959-016-0114-O; Loirat Ch., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):60. DOI:10.1186/1750-1172-6-60; Kavanagh D., Goodship T.H., Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508–530.; Noris M., Remuzzi G. Atypical hemolytic uremic syndrome. N Engl J Med. 2009;361(17):1676–1687. DOI:10.1056/NEJMra0902814; Hossain M.A., Cheema A., Kalathil Sh., Bajwa R., Costanzo E.J., Cosentino J., Cheng J., Vachharajani T., Asif A. Atypical hemolytic uremic syndrome: Laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations. Saudi Journal of Kidney Diseases and Transplantation. 2018;29(2):276–283.; Phillips E.H., Westwood J.P., Brocklebank V., Wong E.K.S., Tellez J.O., Marchbank K.J., McGuckin S., Gale D.P., Connolly J., Goodship T.H.J., Kavanagh D., Scully M.A. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost. 2016;14(1):175–185. DOI:10.1111/ith.13189; Козловская Н.Л., Коротчаева Ю.В., Боброва Л.А., Шилов Е.М. Акушерский атипичный гемолитико-уремический синдром: первый российский опыт диагностики и лечения. Нефрология. 2016;20(2):68–80 [Kozlovskaya N.L., Korotchaeva Y.V., Bobrova L.A., Shylov E.M. Atypical hemolytic-uremic syndrome in obstetric practice: the first Russian experience of diagnosis and treatment. Nephrology = Nefrologiya. 2016;20(2):68–80 (In Russ.)]. DOI:10.17116/rosakush201616695-104; Van Laecke S., Van Biesen W. Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney Int. 2017;91:1271–1274.; Демьянова К.А., Козловская Н.Л., Боброва Л.А., Козлов Л.В., Андина С.С., Юрова В.А., Кучиева А.М., Рощупкина С.В., Шилов Е.М. Сравнительный анализ изменений в системе комплемента при катастрофическом антифосфолипидном синдроме и атипичном гемолитико-уремическом синдроме. Вестник РАМН. 2017;72(1):42–52 [Demyanova K.A., Kozlovskaya N.L., Bobrova L.A., Kozlov L.V., Andina S.S., Yurova V.A., Kuchieva A.M., Roshchupkina S.V., Shilov E.M. Comlement system abnormalities in patients with atypical hemolytic uremic syndrome and catastrophic antiphospholipid syndrome. Annals of Russian Academy of Medical Sciences = Vestnik Rossiyskoy akademii meditsinskikh nauk. 2017;72(1):42–52 (In Russ.)]. DOI:10.15690/vramn769; Meola M., Samoni S., Petrucci I., Ronco C. Clinical scenarios in acute kidney injury-Parenchymal acute kidney injury-Vascular diseases. Contrib Nephrol. 2016;188:48–63. DOI:10.1159/000445467; Meola M., Petrucci I. Ultrasound and color Doppler in nephrology. Acute kidney injury. G Ital Nefrol. 2012;29(5):599–615.; Capotondo L., Nicolai G.A., Garosi G. The role of color Doppler in acute kidney injury. Arch Ital Urol Androl. 2010; 82(4):275–279.; Boddi M. Renal ultrasound (and Doppler sonography) in hypertension: an update. Adv Exp Med Biol. 2017;956:191–208. DOI:10.1007/5584_2016_170; Reising A., Hafer C., Hiss M., Kielstein J.T., Menne J., Gueler F., Beneke J., Linnenweber-Held S., Haller H., Einecke G. Int Urol Nephrol. 2016;48(4):561–570. DOI:10.1007/s11255-015-1194-7; Тарасова Л.Н., Киселева Т.Н., Фокин А.А. Глазной ишемический синдром. Москва: Медицина, 2003. 176 с. [Tarasova L.N., Kiseleva T.N., Fokin A.A. Ocular ischemic syndrome. M: Medicine, 2003. 176 p. (In Russ.)].; Tranquart F., Berges O., Koskas P., Arsene S., Rossazza C., Pisella P.J., Pourcelot L. Color doppler imaging of orbital vessels: personal experience and literature review. J Clin Ultrasound. 2013;31(5):258–273. DOI:10.1002/jcu.10169; Смирнова Т.В., Аветисов С.Э., Козловская Н.Л., Киселева Т.Н., Иванова М.Е., Кравчук Е.А. Цветовое доплеровское картирование в оценке состояния кровотока в сосудах глаза у пациентов с антифосфолипидным синдромом. Рефракционная хирургия и офтальмология. 2006;6(4):39–42 [Smirnova T.V., Avetisov S.E., Kozlovskaya N.L., Kiselyova T.N., Ivanova M.E., Kravchuk E.A. Color Doppler imaging in evaluation of ocular dynamics in patients with antiphospholipid syndrome. Refractive Surgery and Ophthalmology = Refrakcionnaya hirurgiya i oftalmologiya. 2006;6(4):39–42 (In Russ.)].; Бышевский А.Ш., Терсенов О.А. Биохимия для врача. Екатеринбург: Уральский рабочий, 1994. 384 с. [Byshevskij A.Sh., Tersenov O.A. Biochemistry for the doctor. Yekaterinburg: Uralskij rabochij, 1994. 384 p. (In Russ.)].; https://www.ophthalmojournal.com/opht/article/view/772

  2. 2
    Academic Journal

    Source: Rational Pharmacotherapy in Cardiology; Vol 14, No 3 (2018); 370-378 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 3 (2018); 370-378 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-3

    File Description: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1692/1657; Maron B.J., Maron M.S. A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(12):1897-907. doi:10.1016/j.amjcard.2016.08.086.; Frustaci A., Francone M., Petrosillo N., Chimenti C. High prevalence of myocarditis in patients with hypertensive heart disease and cardiac deterioration. Eur J Heart Fail. 2013;15(3):284-91. doi:10.1093/eurjhf/hfs169.; Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.; Rosmini S., Biagini E., O'Mahony C. et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart. 2017;103(4):300-6. doi:10.1136/heartjnl2016-310138.; Blagova O.V., Nedostup A.V., Kogan E.A. et al. The Materials of Russian national congress of cardiology "Innovations and progress in cardiology" (Kazan, September 24-26, 2014). Kazan: RCS; 2014: P. 82. (In Russ) [Благова О.В., Недоступ А.В., Коган Е.А. и др. Результаты клинико-морфологической диагностики при первичном синдроме гипертрофии миокарда. Материалы Российского национального конгресса кардиологов «Инновации и прогресс в кардиологии» (Казань, 24-26 сентября 2014 г.). Казань: РКО; 2014: С. 82].; Menon S., Goyal P., Suryawanshi P. et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol. 2014; 57(1):19-23. doi:10.4103/0377-4929.130873.; Kouba E., Cheng L. Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics. Endocr Pathol. 2016;27(3):188-99. doi:10.1007/s12022-016-9444-5.; Beilan J.A., Lawton A., Hajdenberg J., Rosser C.J. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol. 2013;13:22.doi:10.1186/1471-2490- 13-22.; Li Y., Guo A., Tang J. et al. Evaluation of sonographic features for patients with urinary bladder paraganglioma: a comparison with patients with urothelial carcinoma. Ultrasound Med Biol. 2014;40(3):478-84. doi:10.1016/j.ultrasmedbio.2013.10.014.; Ferreira V.M., Marcelino M., Piechnik S.K. et al. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. J Am Coll Cardiol. 2016; 67(20):2364-74. doi:10.1016/j.jacc.2016.03.543; Giavarini A., Chedid A., Bobrie G. et al. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart. 2013;99(19):1438-44. doi:10.1136/heartjnl-2013-304073.; Gagnon N., Mansour S., Bitton Y., Bourdeau I. Takotsubo-like cardiomyopathy in a large cohort of patients with pheochromocytoma and paraganglioma. Endocr Pract. 2017;23(10):1178-1192. doi:10.4158/EP171930.OR.; Imaoka C., Kanemoto N. [Pheochromocytoma with normal blood pressure and dilated cardiomyopathy: a case report]. J Cardiogr. 1986;16(3):735-45.; Brilakis E.S., Young W.F.Jr., Wilson J.W. et al. Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistent or paroxysmal hypertension. J Heart Lung Transplant. 1999;18(4):376-80.; Yu R., Nissen N.N., Bannykh S.I. Cardiac complications as initial manifestation of pheochromocytoma: frequency, outcome, and predictors. Endocr Pract. 2012;18(4):483-92. doi:10.4158/EP11327.OR.; Zhang R., Gupta D., Albert S.G. Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. Int J Cardiol. 2017; 249:319-323. doi:10.1016/j.ijcard.2017.07.014.; https://www.rpcardio.com/jour/article/view/1692

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7